CoChat

Exosomes in Alzheimer’s Disease: From Being Pathological Players to Potential Diagnostics and Therapeutics

Open access

The DOI matches its Crossref record; 151 of the 154 references it cites were found in a registry or an index.

Abstract

Exosomes (EXOs) were given attention as an extracellular vesicle (EV) with a pivotal pathophysiological role in the development of certain neurodegenerative disorders (NDD), such as Parkinson’s and Alzheimer’s disease (AD). EXOs have shown the potential to carry pathological and therapeutic cargo; thus, researchers have harnessed EXOs in drug delivery applications. EXOs have shown low immunogenicity as natural drug delivery vehicles, thus ensuring efficient drug delivery without causing significant adverse reactions. Recently, EXOs provided potential drug delivery opportunities in AD and promising future clinical applications with the diagnosis of NDD and were studied for their usefulness in disease detection and prediction prior to the emergence of symptoms. In the future, the microfluidics technique will play an essential role in isolating and detecting EXOs to diagnose AD before the development of advanced symptoms. This review is not reiterative literature but will discuss why EXOs have strong potential in treating AD and how they can be used as a tool to predict and diagnose this disorder.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms221910794

Cites

151 of 151 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 The pathological role of exosomes in AD. NMDA: N-methyl-D-aspartate receptor, CDK5: cyclin-dependent kinase 5, P25: protein 25, Aβ: amyloid-beta, APP: amyloid precursor protein, NFT: neurofibrillary tangles, BACE-1: beta-site amyloid precursor protein cleaving enzyme 1. 636 × 408 mm (118 × 118 DPI).
Figure 1 The pathological role of exosomes in AD. NMDA: N-methyl-D-aspartate receptor, CDK5: cyclin-dependent kinase 5, P25: protein 25, Aβ: amyloid-beta, APP: amyloid precursor protein, NFT: neurofibrillary tangles, BACE-1: beta-site amyloid precursor protein cleaving enzyme 1. 636 × 408 mm (118 × 118 DPI).CC BY · PubMed Central
Figure 2 The separation and drug loading techniques for exosomes. 475 × 872 mm (118 × 118 DPI).
Figure 2 The separation and drug loading techniques for exosomes. 475 × 872 mm (118 × 118 DPI).CC BY · PubMed Central
Figure 3 Therapeutic application of exosomes in AD. BCL2: B-cell lymphoma 2, BaX: BcL-2-associated X protein, STAT: signal transduction and activator of transcription protein, NF-κB: nuclear factor kappa-light-chain enhancer of activated B-cells, QU: quercetin, Cur: curcumin, BBB: blood–brain barrier, NFT: neurofibrillary tangles, MP-MSCs: multipotent mesenchymal stem cells, NEP: neprilysin, BACE-1: beta-site amyloid precursor protein cleaving enzyme 1, APP: amyloid precursor protein, Aβ: amyloid-beta, NSCs: neural stem cells, ECVs: extracellular vesicles. 1081 × 540 mm (118 × 118 DPI).
Figure 3 Therapeutic application of exosomes in AD. BCL2: B-cell lymphoma 2, BaX: BcL-2-associated X protein, STAT: signal transduction and activator of transcription protein, NF-κB: nuclear factor kappa-light-chain enhancer of activated B-cells, QU: quercetin, Cur: curcumin, BBB: blood–brain barrier, NFT: neurofibrillary tangles, MP-MSCs: multipotent mesenchymal stem cells, NEP: neprilysin, BACE-1: beta-site amyloid precursor protein cleaving enzyme 1, APP: amyloid precursor protein, Aβ: amyloid-beta, NSCs: neural stem cells, ECVs: extracellular vesicles. 1081 × 540 mm (118 × 118 DPI).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 151 references

Cited by

See all 81

Metadata

Authors
Soliman, H. M., Ghonaim, G. A., Gharib, S. M., Chopra, H., Farag, A. K., Hassanin, M. H., Nagah, A., Emad-Eldin, M., Hashem, N. E., Yahya, G., Emam, S. E., Hassan, A. E. A., & Attia, M. S.
Affiliations
  • Zagazig University (EG)
  • Chitkara University (IN)
Corresponding author
Attia, Mohamed S.
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2021-10-06
Volume
22
Issue
19
Pages
10794
ISSN
1422-0067 (ISSN-L)
OpenAlex
W3202186439
Cited by
81
References
154
Citations by year
2026: 13 · 2025: 17 · 2024: 19 · 2023: 17 · 2022: 14 · 2021: 1
FWCI
1.34
Type
journal article
Language
en
Open access
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
Keywords
exosomes, Alzheimer's disease, extracellular vesicles, drug delivery, neurodegenerative diseases, biomarkers, early diagnosis, microfluidics, exosome isolation, immunogenicity, therapeutics
MeSH terms
Alzheimer Disease, Animals, Humans, Exosomes

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Exosomes in Alzheimer’s Disease: From Being Pathological Players to Potential Diagnostics and Therapeutics. https://app.cochat.ai/papers/10.3390/ijms221910794
The paper
Soliman, H. M., Ghonaim, G. A., Gharib, S. M., Chopra, H., Farag, A. K., Hassanin, M. H., Nagah, A., Emad-Eldin, M., Hashem, N. E., Yahya, G., Emam, S. E., Hassan, A. E. A., & Attia, M. S. (2021). Exosomes in Alzheimer’s Disease: From Being Pathological Players to Potential Diagnostics and Therapeutics. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms221910794

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.